Breaking News Instant updates and real-time market news.

AMGN

Amgen

$161.87

-2.42 (-1.47%)

, DD

DuPont

$69.14

1 (1.47%)

16:01
10/14/16
10/14
16:01
10/14/16
16:01

Amgen names former DuPont CEO Kullman to board

Amgen (AMGN) announced the appointment of Ellen J. Kullman to the Amgen board of directors, effective Oct. 14, 2016. Kullman will serve as a member of the Audit Committee and the Governance and Nominating Committee of the board. Following the appointment of Kullman, the board will comprise 14 directors, 13 of whom are independent. Kullman is the former president, chair and chief executive officer of DuPont (DD), where she served from January 2009 to October 2015.

AMGN

Amgen

$161.87

-2.42 (-1.47%)

DD

DuPont

$69.14

1 (1.47%)

  • 05

    Nov

  • 06

    Nov

  • 19

    Jul

AMGN Amgen
$161.87

-2.42 (-1.47%)

09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.
09/27/16
PIPR
09/27/16
NO CHANGE
PIPR
Overweight
Amgen's Kyprolis in good shape despite trial miss, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Amgen's Kyprolis is still likely to be viewed as a "potent backbone, with the right drugs" after a Phase 3 study in front-line myeloma failed to reach its primary endpoint. The analyst believes the impact of the failed trial on Kyprolis use will be limited and he reiterates an Overweight rating on Amgen.
09/27/16
GSCO
09/27/16
NO CHANGE
Target $206
GSCO
Conviction Buy
Goldman surprised by Amgen's Kyprolis outcome in first-line multiple myeloma
Last night, Amgen announced Phase 3 Kypolis CLARION study did not meet the primary endpoint in first-line multiple myeloma. Goldman analyst Terence Flynn was surprised by this outcome given the prior positive superiority data for Kyprolis versus Velcade in the Phase III ENDEAVOR trial. Flynn sees risk to his Kyprolis $1B sales estimate in a first-line setting, but awaits for additional details from the call and further information regarding another ongoing Phase III trial. He expects Amgen shares to be weak on the news but said the company has additional drivers beyond Kyprolis including Repatha for high cholesterol and Erenumab for migraine with additional data expected in 2H 2016 and Q1 2017. Flynn remains Conviction Buy rated on Amgen and maintains his $206 price target.
09/01/16
09/01/16
NO CHANGE

Amgen's sBLA for Blincyto approved by FDA
Amgen's supplemental Biologics License Application for Blincyto has been approved by the FDA to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL. Blincyto was granted breakthrough therapy, priority review and orphan drug designations by FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. In November 2015, BLINCYTO was granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-cell precursor ALL.
DD DuPont
$69.14

1 (1.47%)

10/10/16
UBSW
10/10/16
UPGRADE
Target $62
UBSW
Buy
Dow Chemical upgraded to Buy from Neutral at UBS
UBS analyst John Roberts upgraded Dow Chemical (DOW) to Buy saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." The analyst sees $3B in potential cost savings and expects improving cash flow. Roberts raised his price target for the shares to $62 from $53.
10/03/16
10/03/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dow Chemical (DOW) and DuPont (DD) were upgraded to Buy from Neutral at Citi with analyst P.J. Juvekar citing he opportunity presented by the proposed merger. 2. Freeport McMoRan (FCX), Barrick Gold (ABX), and Pan American Silver (PAAS) were upgraded to Buy from Hold at Deutsche Bank. 3. LogMeln (LOGM) upgraded to Overweight from Equal Weight at Barclays with analyst Raimo Lenschow saying the pending merger with Citrix's (CTXS) divested GoTo assets creates a "great new opportunity." 4. Halliburton (HAL) upgraded to Buy from Hold at Societe General. 5. Coty (COTY) upgraded to Buy from Neutral at BofA/Merrill with analyst Olivia Tong saying she believes Coty is at the beginning of a potential transformation with the pending closure of the P&G Beauty deal this week that could bring increased scale as well as a more targeted operational structure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
SBSH
10/03/16
UPGRADE
SBSH
Buy
Citi upgrades Dow and DuPont, says DowDuPont could be 'stock to own' in 2017
As previously reported, Citi analyst P.J. Juvekar upgraded shares of both Dow Chemical (DOW) and DuPont (DD), each to Buy from Hold, citing their "massive" cost-cutting opportunity after their proposed merger goes through as well as the potential for upside to the companies' stated $3B synergy target. If their deal gets completed, the combined Dow-DuPont would "be the stock to own in 2017," said Juvekar, who raised the firm's price target on DuPont shares to $76 from $72 and increased the target for Dow shares to $59 from $55.
10/03/16
SBSH
10/03/16
UPGRADE
SBSH
Buy
Dow Chemical upgraded to Buy from Neutral at Citi
Citi analyst P.J. Juvekar upgraded Dow Chemical (DOW) to Buy from Hold citing the opportunity presented by the proposed merger with DuPont (DD). The analyst also upgraded DuPont to Buy from Hold this morning.

TODAY'S FREE FLY STORIES

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

16:58
12/08/16
12/08
16:58
12/08/16
16:58
Hot Stocks
Breaking Hot Stocks news story on Duluth Holdings »

Duluth Holdings down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

CFR

Cullen/Frost

$88.38

1.92 (2.22%)

16:55
12/08/16
12/08
16:55
12/08/16
16:55
Syndicate
Breaking Syndicate news story on Cullen/Frost »

Cullen/Frost files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

DTEA

DAVIDsTEA

$9.30

0.15 (1.64%)

16:49
12/08/16
12/08
16:49
12/08/16
16:49
Hot Stocks
DAVIDsTEA appoints Christine Bullen interim president and CEO »

As previously announced,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ISIL

Intersil

$22.25

0.05 (0.23%)

16:49
12/08/16
12/08
16:49
12/08/16
16:49
Hot Stocks
Intersil stockholders approve merger proposal with Renesas Electronics »

Intersil stockholders…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

DTEA

DAVIDsTEA

$9.30

0.15 (1.64%)

16:47
12/08/16
12/08
16:47
12/08/16
16:47
Earnings
DAVIDsTEA sees FY16 EPS C35c-C40c »

Sees FY16 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

TEL

TE Connectivity

$70.60

0.14 (0.20%)

16:45
12/08/16
12/08
16:45
12/08/16
16:45
Hot Stocks
TE Connectivity raises quarterly dividend to 40c per share from 37c »

TE Connectivity's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

16:41
12/08/16
12/08
16:41
12/08/16
16:41
Earnings
Duluth Holdings sees FY16 adjusted EBITDA $34M-$38M »

Seees FY16 GAAP EPS in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

16:39
12/08/16
12/08
16:39
12/08/16
16:39
General news
Fed Balance Sheet Level data reported »

Week of 12/7 Fed Balance…

16:39
12/08/16
12/08
16:39
12/08/16
16:39
General news
Money Supply M2 Weekly Change data reported »

Week of 11/28 Money…

ENZ

Enzo Biochem

$7.48

0.2 (2.75%)

, BDX

Becton Dickinson

$163.64

-0.35 (-0.21%)

16:38
12/08/16
12/08
16:38
12/08/16
16:38
Earnings
Enzo Biochem reports Q1 adjusted EPS (3c), one estimate (5c) »

Reports Q1 revenue…

ENZ

Enzo Biochem

$7.48

0.2 (2.75%)

BDX

Becton Dickinson

$163.64

-0.35 (-0.21%)

RHHBY

Roche

$27.08

-0.36 (-1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CNS

Cohen & Steers

$37.23

0.48 (1.31%)

16:37
12/08/16
12/08
16:37
12/08/16
16:37
Hot Stocks
Cohen & Steers reports AUM of $56.5B as of November 30 »

Cohen & Steers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$73.05

0.39 (0.54%)

16:37
12/08/16
12/08
16:37
12/08/16
16:37
Hot Stocks
NJ American Water to invest $3.6M in Somerset County »

New Jersey American Water…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DEI

Douglas Emmett

$38.61

0.25 (0.65%)

16:34
12/08/16
12/08
16:34
12/08/16
16:34
Hot Stocks
Douglas Emmett increases quarterly cash dividend to 23c per share »

Douglas Emmett has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRIX

IRIDEX

$15.51

0.61 (4.09%)

16:34
12/08/16
12/08
16:34
12/08/16
16:34
Syndicate
IRIDEX announces offering of common stock, no amount given »

IRIDEX expects to use the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BURL

Burlington Stores

$88.47

0.47 (0.53%)

, BLK

BlackRock

$390.33

12.81 (3.39%)

16:33
12/08/16
12/08
16:33
12/08/16
16:33
Hot Stocks
Frank Cooper III resigns from Burlington Stores board of directors »

Burlington Stores (BURL)…

BURL

Burlington Stores

$88.47

0.47 (0.53%)

BLK

BlackRock

$390.33

12.81 (3.39%)

TJX

TJX

$77.98

-0.21 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STBZ

State Bank Financial

$26.90

0.51 (1.93%)

16:33
12/08/16
12/08
16:33
12/08/16
16:33
Hot Stocks
State Bank Financial reports FDIC approval for previously announced transaction »

State Bank Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MED

Medifast

$40.65

0.86 (2.16%)

16:32
12/08/16
12/08
16:32
12/08/16
16:32
Hot Stocks
Medifast raises quarterly dividend 28% to 32c per share »

Medifast announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

BEN

Franklin Resources

$42.02

1.4 (3.45%)

16:32
12/08/16
12/08
16:32
12/08/16
16:32
Hot Stocks
Franklin Resources reports month-end AUM of $714.4B »

Franklin Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APPY

Venaxis

$3.95

-0.28 (-6.62%)

16:32
12/08/16
12/08
16:32
12/08/16
16:32
Hot Stocks
Venaxis changing name and NASDAQ ticker symbol »

Venaxis has changed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECL

Ecolab

$119.61

0.8 (0.67%)

16:31
12/08/16
12/08
16:31
12/08/16
16:31
Hot Stocks
Ecolab raises quarterly dividend 6% to 37c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

16:30
12/08/16
12/08
16:30
12/08/16
16:30
Options
Preliminary option volume of 19.3M today »

Preliminary option volume…

BBRY

BlackBerry

$7.83

0.2 (2.62%)

16:27
12/08/16
12/08
16:27
12/08/16
16:27
Hot Stocks
BlackBerry unveils mobile-security platform for the enterprise of things »

BlackBerry unveiled its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

MCC

Medley Capital

16:25
12/08/16
12/08
16:25
12/08/16
16:25
Earnings
Medley Capital reports Q4 EPS 23c, consensus 22c »

Reports Q4 net asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

TAHO

Tahoe Resources

$10.01

-0.03 (-0.30%)

, BLK

BlackRock

$390.33

12.81 (3.39%)

16:24
12/08/16
12/08
16:24
12/08/16
16:24
Hot Stocks
Breaking Hot Stocks news story on Tahoe Resources, BlackRock »

BlackRock cuts passive…

TAHO

Tahoe Resources

$10.01

-0.03 (-0.30%)

BLK

BlackRock

$390.33

12.81 (3.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTS

Preferred Apartment

$13.80

-0.09 (-0.65%)

16:23
12/08/16
12/08
16:23
12/08/16
16:23
Recommendations
Preferred Apartment analyst commentary  »

Preferred Apartment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.